<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01821625</url>
  </required_header>
  <id_info>
    <org_study_id>STU 032013-020</org_study_id>
    <nct_id>NCT01821625</nct_id>
  </id_info>
  <brief_title>Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C</brief_title>
  <acronym>SQUELCH-C</acronym>
  <official_title>Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will provide chronic hepatitis C patients with low platelets (less than 75x10^9/L)
      the opportunity to undergo treatment and possible cure of their virus. The main hepatitis C
      drugs will be administered as standard of care, with the addition of the study drug
      eltrombopag.

      The investigators hypothesize that providing eltrombopag to chronic hepatitis C patients with
      low platelets (less than 75x10^9/L) will permit the initiation and completion of antiviral
      triple therapy with boceprevir, ribavirin, and pegylated-interferon.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SQUELCH-C is an investigator-initiated, single arm, non-blinded pilot study on the use of
      eltrombopag in combination with ribavirin, pegylated-interferon, and boceprevir, for patients
      who would not otherwise be treatment candidates because of low platelet counts (less than
      75x10^9/L).

      Administration of the drugs ribavirin and boceprevir will be standard of care, with one
      exception for interferon.

      The total drug treatment period for the study patient will range from 32 - 56 weeks,
      depending on liver disease stage and viral response. Follow-up will take place at 12 and 24
      weeks post treatment to evaluate for sustained viral response. Total study participation may
      require 1.5 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interferon use for hepatitis C plummeted, eliminating the need for study drug.
  </why_stopped>
  <start_date type="Actual">April 2013</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Study Patients Completing Antiviral Therapy, as Per Boceprevir Prescribing Guidelines.</measure>
    <time_frame>Up to 56 weeks</time_frame>
    <description>The length of therapy will depend on several factors:
Study patient's liver disease status.
Study patient's antiviral response.
Study patient's tolerance to treatment.
One patient completed therapy and experienced a sustained viral response.
A minimum full course of treatment will be 30 weeks, with a maximum of 56 weeks of treatment.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Thrombocytopenia</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Thrombocytopenic (Low Platelet) Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All study patients will undergo intervention in this study.
The intervention will be a lead-in with eltrombopag and antiviral triple therapy (interferon, ribavirin and boceprevir).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eltrombopag</intervention_name>
    <description>Study patients will be provided eltrombopag to raise platelet levels before anti-hepatitis C drugs are initiated, and will continue eltrombopag throughout the study.</description>
    <arm_group_label>Thrombocytopenic (Low Platelet) Patients</arm_group_label>
    <other_name>Promacta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients at least 18 years of age.

          -  Require a platelet count below 75 x 10^9 /L at time of screening.

          -  The patients must meet the eligibility criteria for all drugs involved.

          -  Only genotype 1 (a, b, indeterminate, or mixed).

          -  Confirmed history of chronic hepatitis C.

          -  Cirrhotic patients will be included.

          -  Liver imaging within 1 year to exclude hepatocellular carcinoma (HCC) is required in
             patients with cirrhosis.

          -  Patients without evidence of cirrhosis but meeting platelet criteria will also be
             admitted to study.

          -  Subjects must be able to provide informed consent, comply with drug administration
             instructions, and be able to complete each study visit.

          -  Ability to cover costs of ribavirin, interferon, and boceprevir will also be required.

          -  Female subjects are eligible if: Non-pregnant, non-childbearing potential, or of
             childbearing potential and willing to perform complete abstinence or correctly use a
             form of birth control during intercourse [barrier method, intrauterine device,
             hormonal therapy, or surgical sterilization in females or male partner]. They must
             also be willing to have pregnancy tests performed every 4- weeks until 6 months after
             completion of ribavirin.

          -  Male study participants must agree to use a condom and their female partner must
             partake in one of the contraceptive methods discussed above until 6 months after
             completion of ribavirin therapy.

        Exclusion Criteria:

          -  A history of chronic infection (i.e., HIV or HBV) or a previous organ transplantation.

          -  A history of a platelet disorder.

          -  A poorly controlled underlying medical illness (i.e., diabetes, hypertension, coronary
             artery disease, congestive heart failure, etc.).

          -  Any contraindication to any study drugs as mentioned in their respective prescribing
             information.

          -  Patients with decompensated cirrhosis defined as current evidence for ascites,
             encephalopathy, infection or variceal bleeding. All patients should be considered
             Child-Pugh Class A.

          -  Patients with aminotransferase levels â‰¥ 500 IU/L will be excluded on presumption of
             another active liver disease.

          -  Patients must not be pregnant or nursing.

          -  The study physician maintains the right to exclude a patient for a medical condition
             not listed above or based off laboratory values indicating chronic disease discovered
             at screening.

          -  Patients with eye disease may be excluded from this study if the ophthalmologist does
             not recommend treatment.

          -  Subjects with known hypersensitivity reactions (such as Stevens-Johnson syndrome,
             toxic, epidermal necrolysis, and erythema multiforme to ribavirin) to study drugs or
             any component of the products.

          -  Subjects with autoimmune hepatitis, hemoglobinopathies (e.g., thalassemia major,
             sickle-cell anemia), creatinine clearance less than 50 mL/min.

          -  Co-administration of drugs that are highly dependent on CYP3A4/5 for clearance and
             CYP3A4/5 inducers (See Table 2 in boceprevir prescribing information).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William M Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8887</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 23, 2013</study_first_submitted>
  <study_first_submitted_qc>March 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2013</study_first_posted>
  <results_first_submitted>June 14, 2019</results_first_submitted>
  <results_first_submitted_qc>October 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 22, 2019</results_first_posted>
  <last_update_submitted>October 30, 2019</last_update_submitted>
  <last_update_submitted_qc>October 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thrombocytopenia</keyword>
  <keyword>Hepatitis</keyword>
  <keyword>Platelets</keyword>
  <keyword>Eltrombopag</keyword>
  <keyword>Liver Disease</keyword>
  <keyword>Antiviral Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Thrombocytopenic (Low Platelet) Patients</title>
          <description>All study patients will undergo intervention in this study.
The intervention will be a lead-in with eltrombopag and antiviral triple therapy (interferon, ribavirin and boceprevir).
Eltrombopag: Study patients will be provided eltrombopag to raise platelet levels before anti-hepatitis C drugs are initiated, and will continue eltrombopag throughout the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medical contraindication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Thrombocytopenic (Low Platelet) Patients</title>
          <description>All study patients will undergo intervention in this study.
The intervention will be a lead-in with eltrombopag and antiviral triple therapy (interferon, ribavirin and boceprevir).
Eltrombopag: Study patients will be provided eltrombopag to raise platelet levels before anti-hepatitis C drugs are initiated, and will continue eltrombopag throughout the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="52" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Study Patients Completing Antiviral Therapy, as Per Boceprevir Prescribing Guidelines.</title>
        <description>The length of therapy will depend on several factors:
Study patient's liver disease status.
Study patient's antiviral response.
Study patient's tolerance to treatment.
One patient completed therapy and experienced a sustained viral response.
A minimum full course of treatment will be 30 weeks, with a maximum of 56 weeks of treatment.</description>
        <time_frame>Up to 56 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thrombocytopenic (Low Platelet) Patients</title>
            <description>All study patients will undergo intervention in this study.
The intervention will be a lead-in with eltrombopag and antiviral triple therapy (interferon, ribavirin and boceprevir).
Eltrombopag: Study patients will be provided eltrombopag to raise platelet levels before anti-hepatitis C drugs are initiated, and will continue eltrombopag throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Study Patients Completing Antiviral Therapy, as Per Boceprevir Prescribing Guidelines.</title>
          <description>The length of therapy will depend on several factors:
Study patient's liver disease status.
Study patient's antiviral response.
Study patient's tolerance to treatment.
One patient completed therapy and experienced a sustained viral response.
A minimum full course of treatment will be 30 weeks, with a maximum of 56 weeks of treatment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <desc>No unusual collection of adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Thrombocytopenic (Low Platelet) Patients</title>
          <description>All study patients will undergo intervention in this study.
The intervention will be a lead-in with eltrombopag and antiviral triple therapy (interferon, ribavirin and boceprevir).
Eltrombopag: Study patients will be provided eltrombopag to raise platelet levels before anti-hepatitis C drugs are initiated, and will continue eltrombopag throughout the study.
One subject completed the study as planned. Four subjects had to drop out of the study early for different reasons. One subject was not able to start the hepatitis C triple therapy medications due to a medical condition, two subjects discontinued due to lack of virologic response and one subject discontinued treatment due to side effects.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Variceal hemorrhage</sub_title>
                <description>Self-limited GI bleeding as can be seen in cirrhosis.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <description>Flu like symptoms due to interferon therapy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <description>prior skin ulcer on leg exacerbation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>William M Lee, MD</name_or_title>
      <organization>UT Southwestern Medical Center at Dallas</organization>
      <phone>214 645 6111</phone>
      <email>william.lee@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

